Australian Survey Reveals Biosimilar Awareness, Switching Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients were less concerned about being prescribed a biosimilar if it was a new prescription or "if efficacy on the reference brand had waned." Medical professionals' concerns related to effectiveness, impact on patient outcomes, and switching.
You may also be interested in...
Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged
Australia's new policy of 'a'-flagging biosimilars, or allowing them to be substituted for the prescribed originator drug in the pharmacy, is coming under fire amid concerns that the move is overly driven by economic considerations and may not be the most appropriate way of improving patient access to cheaper biologic medicines.
Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged
Australia's new policy of 'a'-flagging biosimilars, or allowing them to be substituted for the prescribed originator drug in the pharmacy, is coming under fire amid concerns that the move is overly driven by economic considerations and may not be the most appropriate way of improving patient access to cheaper biologic medicines.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.